HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


E.l.f. Cosmetics Bold Amid Recession Fears, Forecasting Net Sales Growth Up To 12% In FY 2023

Executive Summary

The Gen Z-beloved maker of prestige-inspired cosmetics and skin care at accessible prices has been experiencing strong sales growth in Target stores, increased business online, and remains confident in its prospects even after recently raising products on two-thirds of its portfolio in response to inflationary pressures.

You may also be interested in...

E.l.f. Hoists 2023 Full-Year Sales Guidance As Value Prices Attract New Customers

E.l.f. Beauty’s sales grew 26% to $122.6m in the fiscal 2023 first quarter, leading the Oakland, CA-based firm to increase full-year projections. According to company leadership, e.l.f. is capturing market share at a rapid clip while expanding distribution, notably in pharmacy retail.

E.l.f. Cosmetics Gets Serious About Skin Care With New Product Launches, Awareness Campaign

E.l.f. Skin, now the fourth brand in the firm’s portfolio alongside e.l.f. Beauty, W3ll People, and Keys Soulcare, includes new Blemish Breakthrough and Pure Skin lines of clean, kind products priced at $14 or less.

E.l.f. Cosmetics Will Be Selectively Less Affordable Come March

E.l.f. will raise prices by $1 across SKUs where it has the most pricing power, while maintaining its lowest-priced items where they are now, CEO Tarang Amin said during the firm’s fiscal 2022 third-quarter earnings call. The company raised guidance for the full year, now targeting net sales up to $379m.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts